A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator Controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU -LINK)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Nov 2019
Price : $35 *
At a glance
- Drugs V 114 (Primary) ; Pneumococcal 13-valent CRM197 vaccine conjugate
- Indications Pneumococcal infections
- Focus Adverse reactions; Registrational
- Acronyms PNEU-LINK
- Sponsors Merck Sharp & Dohme
- 19 Nov 2019 Planned End Date changed from 28 May 2021 to 21 May 2021.
- 19 Nov 2019 Planned primary completion date changed from 28 May 2021 to 21 May 2021.
- 04 Nov 2019 Status changed from recruiting to active, no longer recruiting.